Genentech's giredestrant cuts breast cancer recurrence risk by 30%

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Genentech's giredestrant cuts breast cancer recurrence risk by 30%

Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer

December 10, 2025 8:20 AM EST

Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years

Transformational results support the potential of giredestrant to become a new standard-of-care for early-stage disease

ER-positive breast cancer accounts for approximately 70% of breast cancer cases, and up to a third experience recurrence on or after adjuvant endocrine therapy treatment

Data will be featured in an oral presentation at the 2025 San Antonio Breast Cancer Symposium and included in the official... More